Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Hochintensives Intervalltraining bei jungen erwachsenen Überlebenden von pädiatrischen Hirntumoren: Eine Pilot-Machbarkeitsstudie (HYPE)

3. November 2026 aktualisiert von: Christina Dieli-Conwright, PhD, Dana-Farber Cancer Institute

Hochintensives Intervalltraining bei jungen erwachsenen Überlebenden von pädiatrischen Hirntumoren: Eine Pilot-Machbarkeitsstudie (HYPE)

The purpose of this study is to determine whether a 16-week virtual, home-based, high-intensity interval training (HIIT) exercise program will improve physical, cognitive, and emotional health among young adult survivors of pediatric brain tumors.

The names of the study interventions involved in this study are/is:

  • High-Intensity Interval Training (HIIT)

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This is a Pilot/Feasibility, randomized control, research study that will compare an exercise group to a control group on physical, social, and overall quality of life needs of pediatric brain tumor survivors who are now young adults.

Participants will be randomized (selected at random) for two groups: HIIT program group will complete a 16-week intervention period followed by a 16-week period with no intervention and the waitlisted control group will complete a 16-week period and will perform their usual, daily activities followed by an optional 16-week period in which they can complete the HIIT program.

Research procedures include screening for eligibility, study treatment including in-clinic evaluations of fitness and strength, blood collection, at-home zoom exercise sessions, self-administered activity logs, and survey questionnaires.

Participation in this research study is expected to last about 8 months.

It is expected that about 30 people will take part in this research study.

The Stahl Family Charitable Foundation, Pedal 4 Pediatrics, and the Childhood Brain Tumor Foundation are supporting this research study by providing funding for the study.

Studientyp

Interventionell

Einschreibung (Geschätzt)

30

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 45 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Written informed consent prior to any study-related procedures.
  • At time of study are a young adult, aged 18-45 years.
  • Histologically diagnosed brain tumor during childhood, or currently diagnosed with an IDH-mutant glioma (diagnosed > 18 years).
  • Are at least 2 years post tumor-directed therapy for pediatric brain tumor survivors, or at least 1 year since their most recent surgery, radiation or chemotherapy treatment for IDH-mutant glioma patients (or are deemed able to participate in the study based on the assessment of their treating physician). IDH-mutant glioma patients can participate while on maintenance therapy with an IDH inhibitor.
  • The effects of exercise on the developing fetus are unknown. For this reason, people of child-bearing potential must verify pregnancy status by providing first day of their last menstrual cycle and agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry. Should a person become pregnant or suspect that they are pregnant while participating on the trial, they should inform their treating physician immediately.
  • Medically cleared to participate in exercise by their referring physician or a certified clinical exercise physiologist.
  • If participants have a diagnosis of tumor-related epilepsy, they must have good seizure control, with no generalized seizures in the 6 months preceding enrollment.
  • Are without any other medical conditions that could exacerbate with exercise, such as bone disease (excluding bone metastases) at imminent risk of fracture or uncontrolled cardiopulmonary or metabolic diseases.
  • Speak English and/or Spanish.
  • Currently participate in less than or equal to 60 minutes of moderate or vigorous structured exercise/week.
  • Does not smoke cigarettes or e-cigarettes (no smoking during the previous 12 months). Those who infrequently smoke in social settings will be included. Those who vape will also be included.
  • Willing to travel to DFCI for necessary data collection.
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Diagnosis of primary spinal cord tumor.
  • Pre-existing medical conditions such as uncontrolled tumor-related epilepsy, cardiopulmonary disease, or metabolic diseases that could exacerbate with exercise.
  • Patients with evidence of progressive CNS or systemic cancer in the last 3 months.
  • People who are pregnant, or plan to become pregnant during study duration will be excluded due to the unknown nature of exercise on developing fetuses.
  • Actively on a weight loss diet.
  • Participate in more than 60 minutes of moderate or vigorous structured exercise/week.
  • Currently and regularly smokes.
  • Unable to travel to DFCI for necessary data collection.
  • May not be able to comply with the safety monitoring requirements of the study in the opinion of the investigator.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Unterstützende Pflege
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: HIIT Exercise Program Group

Participants will be randomly assigned to the HIIT exercise group and receive:

  • 3x weekly for 16 week home-based virtually supervised High-Intensity Interval Training.
  • 16-week self-directed exercise follow up period.
  • 3 On-site visits at Week 1, 18 and 34 for assement testing and completion of questionnaires

Exercise program with stationary bike via the Zoom platform.

Andere Namen:
  • Hochintensives Intervalltraining
Aktiver Komparator: Control Group

Participants will be randomly assigned to the HIIT waitlist control group and receive:

  • Daily usual activities
  • 2 On-site visits at Week 1, and 18 for assement testing and completion of questionnaires
  • Option to complete 16 week, 3x weekly HIIT exercise program after initial 16 week period.

Usual Activities

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Attendance of Exercise Sessions
Zeitfenster: From first exercise session to final exercise session, up to 16 weeks

Defined as participant attendance of >= 70% of the 48 HIIT exercise sessions.

From first exercise session to final exercise session, up to 16 weeks
Completion in Minutes of Exercise Sessions
Zeitfenster: From first exercise session to final exercise session, up to 16 weeks

Defined as participant completion of >= 70% of the 90 minutes of exercise per week

From first exercise session to final exercise session, up to 16 weeks
HIIT Compliance
Zeitfenster: From first exercise session to final exercise session, up to 16 weeks

Defined as obtaining +-5W of target power output for >= 40 seconds of high intensity minute

From first exercise session to final exercise session, up to 16 weeks
Barriers to Exercise Adherence
Zeitfenster: From first exercise session to final exercise session, up to 16 weeks

Assessed through the 17-item Barriers to Recruitment Participation Questionnaire (BRPQ), 1-5 scale with 1 denoted as strongly agree and 5 as strongly disagree.

From first exercise session to final exercise session, up to 16 weeks
Participant Burden
Zeitfenster: From first exercise session to final exercise session, up to 16 weeks

Assessed through the Perceived Research Burden Assessment (PRBA), 1-5 scale with 1 denoted as strongly disagree and 5 as strongly agree.

From first exercise session to final exercise session, up to 16 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Cognition
Zeitfenster: : From baseline to post-intervention, up to 43 weeks

An assortment of tests will be executed through the NIH toolbox to measure overall cognition.

: From baseline to post-intervention, up to 43 weeks
Cardiorespiratory Fitness
Zeitfenster: From baseline to post-intervention, up to 43 weeks

Assessed through the use of a VO2 max (or submaximal if equipment is unavailable) cycle exercise stress test (Parvo Medics TrueOne 2400; Sandy, UT, USA).

From baseline to post-intervention, up to 43 weeks
Muscular Strength
Zeitfenster: From baseline to post-intervention, up to 43 weeks

10-repetition maximum will be used to assess muscular strength.

From baseline to post-intervention, up to 43 weeks
Body Composition
Zeitfenster: From baseline to post-intervention, up to 43 weeks

Bioelectrical Impedance Analysis (BIA), and blood pressure as measured twice on both arms with a seated position with a minimum of 1-minute interval and the higher pressure will be recorded when there are differences.

BIA: Assessed via bioelectrical impedance using a validated device (Tanita 780, Arlington Heights, IL). Participants will be asked to remove their shoes and socks after which height will be taken using a stadiometer they will then proceed to move to the BIA and stand still on the device while holding the handles with their hands at their sides. The device will estimate body fat using an algorithm based on their age, sex, height, and body weight.

From baseline to post-intervention, up to 43 weeks
Fatigue
Zeitfenster: From baseline to post-intervention, up to 43 weeks

BFI: A questionnaire of scale ratings 0 - 10 that focuses on cancer-related fatigue and tiredness.

From baseline to post-intervention, up to 43 weeks
Psychosocial Health
Zeitfenster: From baseline to post-intervention, up to 43 weeks

Assessed through the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire, which is comprised of 27 items with scale ratings validated to measure physical, emotional, social, and functional well-being of cancer patients and survivors

From baseline to post-intervention, up to 43 weeks
Quality of Sleep
Zeitfenster: From baseline to post-intervention, up to 43 weeks

Assessed through the Pittsburg Sleep Quality Index (PSQI), which is used to measure 7 components of the quality and patterns of sleep in participants.

From baseline to post-intervention, up to 43 weeks
Dietary Assessment, ASA-24
Zeitfenster: Up to 3 days

Participants will be provided with a login to enter dietary data measured by an automated, online self-administered 24-hour assessment tool.

Up to 3 days
ActiGraph - Physical Activity Monitoring
Zeitfenster: From baseline to post-intervention, up to 27 weeks

Participants will be provided with an accelerometer (ActiGraph, Pensacola, FL) to wear for seven days at baseline and post-intervention testing visits and will be instructed to wear the water-resistant accelerometer at all times except for when swimming or bathing. The device will record activity data and will be electronically transferred to a computer via USB cable at time of completion.

From baseline to post-intervention, up to 27 weeks
Exercise Tolerance
Zeitfenster: From baseline to week 16, up to 32 weeks

Will be recorded using the Exercise-Induced Feeling Inventory (EIF). Based on a 0-4 scale, it assesses the participant's feeling state change(s) post-exercise and is also used for the assessment of self-motivation to adhere to an exercise regimen. Participants will be asked to complete the inventory before and after each exercise session.

From baseline to week 16, up to 32 weeks
Pain Index
Zeitfenster: From baseline to post-intervention, up to 43 weeks

BPI: A 9 item questionnaire to evaluate the severity of pain and the impact of pain on the participant's daily functioning.

From baseline to post-intervention, up to 43 weeks
Hip and Waist Circumference
Zeitfenster: From baseline to post-intervention, up to 43 weeks

Hip and waist circumference will be assessed and recorded in cm.

From baseline to post-intervention, up to 43 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Christina Dieli-Conwright, PhD, MPH, Dana-Farber Cancer Institute

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

4. Dezember 2023

Primärer Abschluss (Geschätzt)

24. September 2027

Studienabschluss (Geschätzt)

24. September 2028

Studienanmeldedaten

Zuerst eingereicht

2. Februar 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. Februar 2023

Zuerst gepostet (Tatsächlich)

23. Februar 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

3. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 22-505

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD-Sharing-Zeitrahmen

Data can be shared no earlier than 1 year following the date of publication

IPD-Sharing-Zugriffskriterien

Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .